Study Summary
Relapsed/refractory leukemia and lymphoma lack effective treatment. The cancer immunotherapy with chimeric antigen receptor (CAR) T cells provides a potent new approach for them. In this clinical trial, the investigators aim to assess the safety and efficacy of administering T cell expressing an anti-CD19 CARs to patients with chemotherapy resistant or refractory CD19 positive B cell malignancy including leukemia and lymphoma.
Want to learn more about this trial?
Request More InfoInterventions
CD19-directed CAR-T cellsBIOLOGICAL
CD19-directed CAR-T cell infusion will be given by vein
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Shanghai Tongji Hospital, Tongji University School of Medicine | Shanghai | China |